clinical trial · NCT05515367
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
Chronic Kidney DiseasesAnemia of Chronic Kidney DiseaseDesidustat
brief summary
A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)
started
Apr 20, 2023
primary completion
Jun 30, 2025
completion
Nov 30, 2025
last updated
Jan 22, 2025
detailed description
The study is being planned to evaluate long term safety of Desidustat with CKD patient.
Total 1004 population i.e 502 dialysis dependent, 502 dialysis independent.
official title
A Phase 4,52 Week, Single Arm,Multicentre Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol